https://www.selleckchem.com/pr....oducts/elexacaftor.h
We showed that the tetravalent construct, F1×F1-hFc, containing two sdAb-in-tandem on an Fc scaffold, exhibits more potent neutralization activity against EVA71 than the bivalent sdAb, F1-hFc, for at least 5.8-fold. We also demonstrated that, using a human scavenger receptor class B member 2 (hSCARB2) transgenic mouse model, a half-dose of the F1×F1-hFc provided better protection against EVA71 infection than did the F1-hFc. Thus, our study furnishes important insights into multivalent sdAb engineering against viral infection and pro
Like
Comment
Share
